Halozyme Therapeutics, Inc.
IT ˙ BIT ˙ US40637H1095
58,52 € 0,00 (0,00%)
2026-06-03
AKTIENPREIS
SecurityIT:1HALO / Halozyme Therapeutics, Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership1,736,501 shares
Latest Disclosed Value $ 116,866,517
Alliancebernstein L.p. reports 5.39% decrease in ownership of 1HALO / Halozyme Therapeutics, Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 1,736,501 shares of Halozyme Therapeutics, Inc. (IT:1HALO) valued at $93,736,324 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,835,486 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of -5.39% during the quarter. The current value of the position is $101,620,039 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,736,501 -98,985 -5.39 116,867 -5.39 0.0378
2026-02-17 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,835,486 -71,869 -3.77 123,528 -11.69 0.0390
2025-11-14 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,907,355 -547,913 -22.32 139,885 9.52 0.0441
2025-08-14 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,455,268 -759,841 -23.63 127,723 -37.74 0.0417
2025-05-15 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,215,109 146,677 4.78 205,156 39.85 0.0742
2025-02-12 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,068,432 -339,909 -9.97 146,702 -24.80 0.0498
2024-11-14 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,408,341 -140,734 -3.97 195,093 4.99 0.0655
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,549,075 -117,249 -3.20 185,830 24.60 0.0648
2024-05-14 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,666,324 202,630 5.85 149,146 16.50 0.0528
2024-02-14 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,463,694 106,918 3.19 128,018 -0.16 0.0493
2023-11-14 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,356,776 2,534,052 308.01 128,229 332.11 0.0545
2023-08-15 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 822,724 7,755 0.95 29,676 -4.65 0.0121
2023-05-15 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 814,969 -2,925 -0.36 31,124 -33.12 0.0133
2023-02-15 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 817,894 -94,205 -10.33 46,538 29.04 0.0209
2022-11-15 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 912,099 -72,135 -7.33 36,064 -16.72 0.0175
2022-08-15 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 984,234 18,363 1.90 43,306 12.43 0.0198
2022-05-13 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 965,871 35,420 3.81 38,519 2.96 0.0149
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 930,451 142,393 18.07 37,413 16.70 0.0132
2021-11-10 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 788,058 238,456 43.39 32,058 28.45 0.0126
2021-07-30 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 549,602 165,870 43.23 24,957 56.00 0.0100
2021-05-06 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 383,732 -55,685 -12.67 15,998 -14.76 0.0070
2021-02-08 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 439,417 157,341 55.78 18,768 153.18 0.0089
2020-11-12 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 282,076 -50,084 -15.08 7,413 -16.75 0.0040
2020-08-13 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 332,160 14,400 4.53 8,905 55.76 0.0052
2020-05-14 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 317,760 -12,500 -3.78 5,717 -2.37 0.0041
2020-02-18 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 330,260 -7,800 -2.31 5,856 11.69 0.0033
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 338,060 0 0.00 5,243 -9.73 0.0033
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 338,060 20,850 6.57 5,808 13.73 0.0036
2019-05-14 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 317,210 1,600 0.51 5,107 10.61 0.0033
2019-02-13 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 315,610 26,786 9.27 4,617 -12.02 0.0034
2018-11-08 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 288,824 -4,360 -1.49 5,248 6.11 0.0034
2018-08-13 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 293,184 19,600 7.16 4,946 -7.72 0.0034
2018-05-14 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 273,584 1,930 0.71 5,360 -2.62 0.0039
2018-02-13 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 271,654 94,960 53.74 5,504 79.34 0.0039
2017-11-13 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 176,694 0 0.00 3,069 35.50 0.0023
2017-08-10 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 176,694 7,500 4.43 2,265 3.28 0.0018
2017-05-11 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 169,194 -4,200 -2.42 2,193 28.02 0.0017
2017-02-13 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 173,394 0 0.00 1,713 -18.23 0.0014
2016-11-10 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 173,394 0 0.00 2,095 40.04 0.0018
2016-08-11 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 173,394 0 0.00 1,496 -8.89 0.0013
2016-05-13 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 173,394 -610 -0.35 1,642 -45.54 0.0014
2016-02-16 2015-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 174,004 -3,490 -1.97 3,015 26.47 0.0026
2016-02-12 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 174,004 2,337
2015-11-13 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 177,494 -19,720 -10.00 2,384 -46.46 0.0020
2015-08-14 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 197,214 0 0.00 4,453 58.13 0.0037
2015-05-13 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 197,214 0 0.00 2,816 47.98 0.0023
2015-02-13 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 197,214 0 0.00 1,903 6.02 0.0016
2014-11-13 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 197,214 0 0.00 1,795 -7.85 0.0015
2014-08-13 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 197,214 9,997 5.34 1,948 -18.08 0.0016
2014-05-13 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 187,217 3 0.00 2,378 -15.25 0.0021
2014-02-13 2013-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 187,214 0 0.00 2,806 35.75 0.0025
2013-11-14 2013-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 187,214 -491 -0.26 2,067 38.72 0.0020
2013-08-13 2013-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 187,705 187,705 1,490 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.